FDA grants breakthrough therapy designation for pirfenidone in unclassifiable interstitial lung disease

Breakthrough designation was granted on the basis of a phase II study which found that, over 24 weeks, pirfenidone provided lower reductions in FVC vs placebo (-87.7mL vs -157.1mL) in this patient cohort.

Source:

Biospace Inc.